The U.S. Food and Drug Administration (FDA) has cleared Bracco Diagnostics' new CardioGen-82 infusion system for cardiac PET myocardial perfusion imaging (MPI). The new infusion system model will replace Bracco's current infusion system.
CardioGen-82 is a closed system used to produce rubidium-82 chloride injection for intravenous administration. The new version has ergonomic details that provide access to all system components while minimizing radiation exposure for staff and patients, Bracco said.
In addition, the new generation has smart features like dosing options and other protocol parameters that improve workflow and eliminate manual record-keeping.
